These acquisitions also bring additional pipeline products. http://madelynfordcity.denaliinstitute.org/2016/09/03/further-advice-on-speedy-systems-of-interview-skillsThese pipeline products should they come to market would be complementary to our current call points including hospitals, physician offices and public health. While it’s still very early in the process, the integration of both businesses is going well and tracking to our integration timelines. Given these recent acquisitions, we’ll now be providing revenue detail by indication. In the third quarter, tuberculosis revenue of $22 million, grew 23% over the prior year, increase was primarily driven by strong growth in the U.S. and Asia. Tick-borne disease and other revenue was $4.1 million, as even in the seasonally strongest quarter, the Imugen business performed ahead of our expectations. Revenues from the Immunetics acquisition which closed after the quarter will be included in our fourth quarter results. medical interview at bristolLooking at third quarter revenue by geography, U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-oxfd-earnings-conference-022051309.html
You may also be interested to read